Cogent Biosciences (COGT) Change in Acquisitions & Divestments (2017 - 2026)

Cogent Biosciences (COGT) has reported Change in Acquisitions & Divestments for 7 consecutive years, with $97.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 39.91% year-over-year to $97.8 million; the TTM figure through Mar 2026 stood at $317.1 million (up 9.25% YoY), while the FY2025 annual figure was $289.2 million, down 1.78% from the prior year.
• Change in Acquisitions & Divestments rose to $97.8 million in Q1 2026 per COGT's latest filing, from $73.3 million in the prior quarter.
• Across five years, Change in Acquisitions & Divestments topped out at $120.0 million in Q1 2023 and bottomed at $22.1 million in Q3 2023.
• Historically, Change in Acquisitions & Divestments has averaged $71.9 million across 4 years, with a median of $73.3 million in 2025.
• On a YoY basis, Change in Acquisitions & Divestments climbed as much as 262.41% in 2024 and fell as far as 38.23% in 2024.
• Cogent Biosciences' Change in Acquisitions & Divestments stood at $61.7 million in 2023, then advanced by 20.66% to $74.5 million in 2024, then slipped by 1.62% to $73.3 million in 2025, then surged by 33.53% to $97.8 million in 2026.
• Business Quant data shows COGT's Change in Acquisitions & Divestments at $97.8 million in Q1 2026, $73.3 million in Q4 2025, and $69.1 million in Q3 2025.